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Results: Patients received sequential (n=49, 32%) or 
concomitant (n=93, 60%) chemo-radiotherapy. Eleven 
patients received radiotherapy alone.. Competing risks 
analysis found a significantly higher rate of ICDM in the AC 
group compared to SCC (p= 0.0004) but no significant 
difference in incidence of ECDM (p=0.08). LR failure was 
higher in SCC than in AC (p=0.01). There was no significant 
difference between the two histology groups in the 
proportion dying without evidence of disease (p=0.3), see 
Figure. Restricting the analysis to patients with distant 
metastases as first site of failure, there was a significantly 
higher rate of cerebral metastases in AC than in SCC (p= 
0.04), cf. Table 1. 
 
Conclusion: The pattern of first failure in inoperable NSCLC 
differs among patients with AC and SCC with intra-cranial 
distant metastases being more common in AC than in SCC and 
LR relapse being much more frequent in SCC than in AC. 
Experimental treatment strategies should be targeting 
different relapse patters in various histological subtypes. 
Intensification of local therapy for example may yield a 
worse risk/benefit ratio in AC compared to SCC.  
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Purpose or Objective: In addition to its curative use in early 
stage lung cancer, stereotactic ablative radiotherapy (SABR) 
can also potentially be indicated for pulmonary 
oligometastatic disease. This study aims to retrospectively 
analyze treatment outcomes and develop nomograms to 
predict survival. 
 
Material and Methods: From September 2012 to April 2015, 
treatment outcomes and toxicities for 85 cases of SABR in 72 
patients retrospectively reviewed. Prognostic factors were 
analyzed via multivariate analyses using Cox proportional 
hazards regression. Using factors that demonstrated to be 
significant in the Cox regression model, nomograms were 
constructed and validated internally. 
 
Results: After a median follow-up of 15 months, only 1 
patient showed local failure within the radiation field. The 
local failure-free survival (LFFS) rate at 2 years was 98%. The 
1-year and 2-year progression-free survival (PFS) and overall 
survival (OS) rates were 62% and 48%, and 90% and 72%, 
respectively. Multivariate analyses demonstrated that 
controlled primary cancer (p = 0.01), absence of 
extrapulmonary metastatic disease (p = 0.03), and disease-
free interval (DFI) longer than 1 year (p < 0.01) favorably 
affects PFS. Furthermore, the absence of extrapulmonary 
metastatic disease (p < 0.01) and lower performance status 
(p = 0.03) increased OS as well. In terms of internal 
validation, nomograms for PFS and OS revealed C-index of 
0.75 and 0.81, and showed a well-fitted calibration curves, 
respectively. Grade 1 or 2 radiation pneumonitis was found in 
37 cases, and grade 1 chest wall pain was found in 1 case. 
Any grade 3 or higher toxicities were not identified. 
 
 
 
 
Conclusion: SABR demonstrated good local control with 
tolerable adverse effects for pulmonary oligometastases. 
Several factors were predictive for survival. Based on these 
factors, nomograms presented in this study can potentially be 
a useful tool for the prediction of progression-free and 
overall survival rates. 
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